Full Breakdown
Moderna's mCombriax Vaccine: A Milestone in Combined COVID-19 and Flu Protection
2/28/2026, 3:50:35 AM
EMA's Recommendation for mCombriax
The European Medicines Agency (EMA) has recommended the approval of Moderna's combined mRNA COVID-19 and flu vaccine, named mCombriax, for individuals aged 50 and older. This marks a significant milestone as it would be the first combined vaccine for these respiratory viruses to receive market authorization in the European Union. The EMA's Committee for Medicinal Products for Human Use (CHMP) based its recommendation on data from a study involving 8,000 participants, which demonstrated that mCombriax generated a stronger antibody response compared to separate vaccinations for COVID-19 and influenza.
Background on Development and Regulatory Challenges
Moderna began developing mCombriax in 2021, with initial Phase 3 trial results reported in 2024. However, the vaccine's path to approval has faced hurdles, particularly in the United States. In 2022, Moderna voluntarily withdrew its application for the combined vaccine after the U.S. Food and Drug Administration (FDA) requested additional data regarding the flu component. The FDA initially refused to review the application, citing concerns over the comparator vaccine used in clinical trials, but later reversed its decision and agreed to evaluate the application.
Key Figures and Market Implications
Moderna's CEO, Stéphane Bancel, emphasized the importance of the EMA's recommendation, stating it represents a crucial step for respiratory virus vaccination and for the company's future. The approval of mCombriax would be Moderna's fourth marketed product in Europe, as the company seeks to diversify its revenue streams amid declining demand for COVID-19 vaccines. Moderna's stock has seen fluctuations, declining nearly 90% from its 2021 highs, but recent developments have sparked optimism among investors.
Criticism and Regulatory Environment
The differing regulatory responses between the EMA and FDA highlight a complex landscape for vaccine approvals. Critics have pointed to the FDA's initial refusal as indicative of a more cautious approach under the current administration, led by Health Secretary Robert F. Kennedy Jr., who has expressed skepticism towards mRNA technology. This skepticism has contributed to a challenging environment for vaccine manufacturers in the U.S., contrasting with the more straightforward approval process in Europe.
What's Next for Moderna
The EMA's recommendation will be forwarded to the European Commission for final approval, which is expected to take some time. Meanwhile, Moderna is also preparing for a potential U.S. launch of its mRNA flu vaccine, with a decision from the FDA anticipated by August 5, 2026. If approved, mCombriax could be available in European markets for the 2026-2027 flu season, providing a new option for older adults seeking protection against both COVID-19 and influenza.
Verbatim Quotes
- “The CHMP’s positive opinion represents an important milestone for respiratory virus vaccination and for Moderna, with the introduction of the world’s first flu plus COVID combination vaccine,” — Stéphane Bancel, CEO of Moderna
- “Combination vaccines have the potential to simplify vaccination and support improved health outcomes.” — Stéphane Bancel, CEO of Moderna
- “Combination vaccines have the potential to simplify vaccination and support improved health outcomes. We appreciate the EMA’s rigorous scientific review.” — Stéphane Bancel, CEO of Moderna
This development not only signifies a potential shift in how respiratory viruses are managed but also reflects the ongoing evolution of vaccine technology in response to public health needs.
